Bladder cancer: nearly 30% of patients fail to complete NACT

  • Hugar LA & al.
  • Urology
  • 10 Nov 2018

  • curated by Deepa Koli
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Nearly 30% of patients with bladder cancer who received neoadjuvant chemotherapy (NACT) failed to complete their regimen.
  • Older age was an independent factor for failure to complete NACT.
  • Significant regional variation was observed; patients from the central United States had lower odds of failure of completing NACT.

Why this matters

  • Identifying risk factors for not completing NACT may help decision making.

Study design

  • 594 patients with bladder cancer underwent cystectomy between 2004 and 2013, and received NACT within 6 months.
  • Funding: None disclosed.

Key results

  • 29% of patients did not complete NACT.
  • Age and geographic region showed independent association with failing to complete NACT:
    • Patients aged ≥80 years were more likely to fail to complete NACT vs those aged 66-69 years (aOR, 2.6; 95% CI, 1.4-4.8).
    • Patients from the central region were less likely to fail to complete NACT vs those from the northeast region (aOR, 0.3; 95% CI, 0.2-0.6).
  • Increased comorbidity was not associated with risk for noncompletion (P>.05).

Limitations

  • Retrospective design.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit